Aprepitant injectable emulsion delivers 130 mg of aprepitant in an 18 mL single-dose vial for intravenous administration. As the active moiety of a prescription antiemetic, aprepitant belongs to a distinct pharmacological class that addresses a specific neurochemical driver of chemotherapy-induced nausea and vomiting (CINV). This article explains the molecular mechanism behind the product and its place within modern antiemetic protocols.

Substance P and the NK1 Receptor Pathway

Nausea and vomiting triggered by cytotoxic chemotherapy are mediated through several neurotransmitter systems. One central player is substance P, a neuropeptide that binds to the neurokinin-1 (NK1) receptor in the brainstem vomiting center and the area postrema. Aprepitant is a selective, high-affinity antagonist of the human substance P / neurokinin-1 receptor. Unlike older supportive agents, it shows little or no affinity for serotonin (5-HT3), dopamine, or corticosteroid receptors, which gives it a targeted mechanistic profile within the antiemetic armamentarium.

Central Action and Blood-Brain Barrier Crossing

Preclinical and human positron emission tomography studies demonstrate that aprepitant crosses the blood-brain barrier and occupies NK1 receptors in the central nervous system. By blocking these receptors, it interrupts the emetic signal that cytotoxic agents such as cisplatin generate via central pathways. This central action is important because CINV has both an acute phase within the first 24 hours and a delayed phase on days two through five, and NK1 blockade addresses the delayed component that serotonin antagonists alone handle less completely.

Placement Within a Triple Regimen

In clinical use, aprepitant is administered as part of a combination that also includes a corticosteroid, such as dexamethasone, and a 5-HT3 receptor antagonist, such as ondansetron. Studies show that NK1 blockade augments the antiemetic activity of both the 5-HT3 antagonist and the corticosteroid. The 130 mg intravenous dose is given as a single infusion or a short injection, typically completed shortly before chemotherapy begins, after which oral therapy is unnecessary for single-dose regimens.

Practical Handling Considerations

The emulsion is provided in a ready-to-use single-dose vial, which reduces pharmacy compounding steps compared with formulations that require bag preparation. Because aprepitant interacts with the CYP3A4 pathway, prescribers review concomitant medications, and the product labeling notes specific cautions such as concurrent pimozide use. These handling and interaction details are part of standard antiemetic safety monitoring rather than the mechanical performance of the vial itself.

FAQ

Q: What receptor does aprepitant block to prevent nausea? A: Aprepitant selectively antagonizes the neurokinin-1 (NK1) receptor for substance P in the central nervous system, interrupting the emetic signal triggered by chemotherapy.

Q: Why is aprepitant given together with other antiemetics? A: It is combined with a corticosteroid and a 5-HT3 antagonist because NK1 blockade complements the activity of those agents and provides coverage for the delayed phase of CINV.

Q: How is the 130 mg injectable emulsion administered? A: The 130 mg dose is supplied in an 18 mL single-dose vial for intravenous use, given as an infusion or a short injection before chemotherapy, without requiring follow-on oral doses in single-dose regimens.